SUBSEQUENT EVENTS |
3 Months Ended |
|---|---|
Mar. 31, 2024 | |
| SUBSEQUENT EVENTS | |
| SUBSEQUENT EVENTS |
NOTE 19 - SUBSEQUENT EVENTS
Subsequent to March 31, 2024, the Company issued an aggregate of 30,926 shares of its common stock for the Company’s President stock compensation and two subscription agreements valued at $31,667.
On April 24, 2024, the Company and Mr. Lucido entered into an exchange agreement whereby the parties agreed to exchange the total of $544,284 owed by the Company, including $426,558 accrued fees pursuant to his Board service, and $117,726 owed by BioCorRx Pharmaceuticals, for 460,477 shares of restricted Common Stock.
On April 24, 2024, the Company and Ms. Felix entered into an exchange agreement whereby the parties agreed to exchange the $265,000 owed by the Company to Ms. Felix as compensation for services rendered for 224,196 shares of restricted Common Stock. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|